Antibiotic Platform System for Rapid Drug-Resistant Bacteria Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing antibiotics are inefficient in addressing drug-resistant pathogenic bacteria, as they require long development times, are costly, and often lead to rapid drug resistance, with a lack of effective antibiotics against highly-drug-resistant Gram-negative bacteria and vancomycin-resistant Staphylococcus aureus.
Innovation Solution
A novel antibiotic preparation method involving the design of recombinant molecular structures with specific recognition and effect regions, using antibody mimetics and colicins to target and kill bacteria, which can be rapidly developed and verified using a platform system comprising goal proposing, designing, and laboratory systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional screening methods are used to develop antibiotics, then the development process is straightforward and based on natural secretions, but the development time is long and the speed cannot keep pace with drug-resistant bacteria mutation
Solution Approach 1:
The patent changes the fundamental parameter of antibiotic development from natural secretion-based screening to genetically engineered production. By modifying bacterial genes to produce novel antibiotics with new chemical structures and mechanisms of action, the development speed increases dramatically while the time loss decreases, keeping pace with drug-resistant bacteria evolution.
Solution Approach 2:
The patent segments the antibiotic development process into modular components: gene selection, genetic engineering, expression system construction, and antibiotic production. This segmentation allows parallel development of multiple antibiotic candidates simultaneously, increasing productivity and reducing overall development time compared to traditional sequential screening.
2Productivity
If gene engineering methods are used to develop novel antibiotics, then the development speed increases, but the pathogenic bacteria still develop drug resistance rapidly
Solution Approach 1:
The patent changes the chemical structure parameters of antibiotics by engineering completely novel molecular structures rather than modifying existing ones. This creates antibiotics with new mechanisms of action that drug-resistant bacteria have not encountered, maintaining reliability against resistant strains while preserving high development speed through genetic engineering.
Solution Approach 2:
The patent uses bacterial gene sequences as templates to engineer novel antibiotics through genetic copying and modification. By copying natural antibiotic gene structures and introducing targeted mutations, the system produces variants that maintain effectiveness against drug-resistant bacteria while accelerating development through standardized genetic engineering protocols.
3Ease of manufacture
If chemical modification of natural antibiotics is used, then the production method is established, but the antibiotics cannot effectively threaten highly-drug-resistant Gram-negative bacteria
Solution Approach 1:
The patent fundamentally changes the production parameter from chemical modification of natural products to direct genetic engineering of antibiotic-synthesizing pathways. This allows production of novel antibiotics with structures too complex for chemical synthesis but easily produced by engineered biological systems, maintaining ease of manufacture while achieving reliability against drug-resistant bacteria through new molecular structures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the rapid development of antibiotics with strong antibacterial effects against drug-resistant bacteria, reducing the likelihood of drug resistance and significantly shortening the development cycle, providing effective alternatives to existing antibiotics.
Implementation Method 1
When said target refers to virus, prokaryotic cell or eukaryotic cell with phospholipid bilayer membranes as the basic structure of its cell membrane or envelope, said pharmaceutical effect refers to causing death and/or collapsing; said effect region refers to bioactive substance which can form ion channel or pore path on phospholipid bilayer membranes
Data Source
AI summary
Provided are a novel antibiotic preparation method and platform system based on the method, belonging to a novel drug development method. The method is based on a fixed structural formula: F—R, wherein F is an effect area, and R is an identification area. At the prior art level, the present invention can quickly develop a specific novel antibiotic for most pathogenic microorganisms or biological cells. Also provided is a platform for implementing the method, ensuring that the novel antibiotic is developed in an efficient streamlined process.